Rocking the boat on rivaroxaban
This presentation is the property of its rightful owner.
Sponsored Links
1 / 33

Rocking the boat on Rivaroxaban PowerPoint PPT Presentation


  • 111 Views
  • Uploaded on
  • Presentation posted in: General

Rocking the boat on Rivaroxaban. Manish Khullar, BSc Pharm Interior Health Pharmacy Resident August 15, 2013. Learning Objectives. Describe the risk assessment of stroke for atrial fibrillation List therapeutic alternatives for stroke prevention

Download Presentation

Rocking the boat on Rivaroxaban

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Rocking the boat on rivaroxaban

Rocking the boat on Rivaroxaban

Manish Khullar, BSc Pharm

Interior Health Pharmacy Resident

August 15, 2013


Learning objectives

Learning Objectives

  • Describe the risk assessment of stroke for atrial fibrillation

  • List therapeutic alternatives for stroke prevention

  • Explain the role of rivaroxaban in patients with atrial fibrillation and aortic valve replacement


Our patient

Our Patient


Anticoagulant history

Anticoagulant history

  • Diagnosed with atrial fibrillation this year and placed on warfarin (INR 2-3) 2 months ago

  • Was on warfarin for 1 month but did not tolerate side effects (insomnia, headaches, vomiting)

  • GP switched him to rivaroxabanlast month and has been on it since admission


Our patient1

Our Patient


Our patient2

Our Patient


Review of systems

Review of Systems


Investigations

Investigations

  • Diagnostics:

    • Chest x-ray (upon admission):

      • Left sided pleural effusion

      • Mild right sided pleural effusion

    • ECHO:

      • Pending

      • Ejection fraction from Jan 2013: 40-45%

    • Endoscopy

      • Pending


Current problems and medications

Current Problems and Medications


Course in hospital

Course in Hospital

  • Admitted to investigate shortness of breath and worsening CHF

  • Endoscopy identified gastric ulcer

  • Transfused with 2 units of blood


List of drps

List of DRPs

  • JF is at risk of stroke secondary to not receiving any anticoagulation therapy for his atrial fibrillation and would benefit from reassessment of his stroke prophylaxis therapy.

  • JF is at risk of stroke secondary to not receiving antithrombotic therapy with AVR and would benefit from reassessment of his stroke prophylaxis therapy.

  • JF is at risk of death and hospitalizations secondary to receiving too low dose of atorvastatin despite his high risk and would benefit from reassessment from his prophylaxis therapy.

  • JF is at risk of death and hospitalizations secondary to not receiving an ACE inhibitor or ARB for MI prophylaxis and would benefit from reassessment of therapy.


List of drps1

List of DRPs

  • JF is at risk of death and hospitalizations secondary to not receiving antiplatelet therapy for post-MI and would benefit from reassessment of therapy.

  • JF is at risk of death and hospitalizations secondary to not receiving an ACE inhibitor or ARB despite having congestive heart failure and would benefit from reassessment of his congestive heart failure therapy.

  • JF is at risk of experiencing adverse effects of metformin secondary to being on metformin despite poor renal function and would benefit from reassessment of his therapy.

  • JF is at an increased risk of bleeding, stroke/death due to unclear efficacy in rivaroxaban in AVR patients and would benefit from reassessment of therapy.


Drp focus

DRP Focus

  • JF is at risk of stroke secondary to not receiving any anticoagulation therapy for his atrial fibrillation and would benefit from reassessment of his stroke prophylaxis therapy.

  • JF is at risk of stroke secondary to not receiving antithrombotic therapy with AVR and would benefit from reassessment of his stroke prophylaxis therapy.

  • JF is at an increased risk of bleeding, stroke/death due to unclear efficacy in rivaroxaban in AVR patients and would benefit from reassessment of therapy.


Background

Background

  • Stroke occurs in atrial fibrillation due to blood stasis in atria leading to clot formation inside the chambers

  • Upon cardioversion to NSR, the clot may eject and stroke can occur


Assessing risk of stroke in atrial fibrillation

Assessing Risk of Stroke in Atrial Fibrillation

  • Stroke assessment tool: CHADS2


Need for a ntithrombotics in avr

Need for Antithrombotics in AVR

  • Patients with prosthetic valves are at risk of thromboembolic complications (stroke, valve obstruction and/or regurgitation)

  • Risk is higher with mechanical valves than with bioprosthetic valves

  • Risk is higher with mitral than aortic prosthetic valves

  • Making antithrombotic therapy necessary in these patients


Goals of therapy

Goals of Therapy

  • Reduce mortality

  • Reduce morbidity (strokes, hospitalizations)

  • Prevent adverse events

  • Improve quality of life


Antithrombotic alternatives for avr

Antithrombotic Alternatives for AVR

  • CHEST guidelines:

    • “in patients with aortic bioprosthetic valves, who are in sinus rhythm, and have no other indication for VKA therapy, we recommend ASA (50-100mg/d)”

CHEST 2008


Antithrombotic alternatives for avr1

Antithrombotic Alternatives for AVR

  • CHEST guidelines:

    • “in patients with bioprosthetic valves who have additional risk factors for thromboembolism, including AF, hypercoaguable state or low ejection fraction, we recommend VKA therapy (target INR 2-3)…low dose aspirin should be considered, particularly in patients with history of atherosclerotic vascular disease. We suggest ASA not be added to long-term VKA therapy in patients with bioprosthetic heart valves who are at particularly high risk of bleeding…”

CHEST 2008


Therapeutic alternatives for atrial fibrillation

Therapeutic Alternatives for Atrial Fibrillation

  • Aspirin

  • Aspirin + Clopidogrel

  • Warfarin

  • Dabigatran

  • Rivaroxaban

  • Apixaban


Clinical question

Clinical Question

  • In a 74 year old patient who is at high risk of ischemic stroke secondary to atrial fibrillation and bioprosthetic aortic valve replacement, is rivaroxaban as compared to warfarin, effective at reducing stroke risk without increasing risk of bleeding?


Literature review

Literature Review


Rocket af

ROCKET-AF

ROCKET-AF. NEJM 2011;10.1056/NEJMoa1009638


Results efficacy

Results: Efficacy

ROCKET-AF. NEJM 2011;10.1056/NEJMoa1009638


Results safety

Results: Safety

ROCKET-AF. NEJM 2011;10.1056/NEJMoa1009638


Study limitations

Study Limitations

  • Methodology:

    • 1 site violated Good Clinical Practice; when patients excluded, should have re-analyzed distribution of baseline characteristics

    • Did not specify in detail who collected the results (more potential for bias)

  • Clinically

    • patients in this study differs to JF (ie. no prosthetic heart valve)

    • patients in the study on warfarin were only in the therapeutic range 55% of the time


  • Assessment of therapeutic alternatives for atrial fibrillatrion

    Assessment of Therapeutic Alternatives for Atrial Fibrillatrion

    http://www.sparctool.com/

    http://www.sparctool.com/


    Assessment of therapeutic alternatives for avr

    Assessment of Therapeutic Alternatives for AVR


    Therapeutic recommendation and justification

    Therapeutic Recommendation and Justification

    • Do not restart rivaroxaban for stroke prophylaxis

    • Suggest starting warfarin at a low dose such as 3mg podaily to target INR 2-3 once clinically stable and active bleeding ruled out


    Monitoring efficacy

    Monitoring: Efficacy

    • S: Ø dizziness, blurred vision, numbness, paralaysis or weakness, fatigue, shortness of breath

    • O: Ø loss of coordination, slurred speech


    Monitoring safety

    Monitoring: Safety

    • S: Dizziness, fatigue, headache, lethargy, GI upset, abdominal pain,

    • O: vitals, Hgb, MCV, INR, AST, ALT, rash, urticaria, bruising


    Follow up

    Follow-up

    • August 12:

      • Discussed pros and cons of warfarin therapy with patient

      • After learning more about the drug and importance of INR monitoring and interactions, the patient and his family were amenable to trying warfarin again

      • Initiated warfarin 3mg po daily with daily INRs


    Questions

    Questions…

    ?


  • Login